A COVID-19 subvariant called BA.3.2, nicknamed “Cicada,” is spreading rapidly across the United States after first being detected in South Africa in November 2024. The strain carries unusual genetic mutations that set it apart from recent variants circulating in the U.S., and health authorities are now racing to determine how well existing vaccines hold up against it. For Americans wondering whether their latest cough or fever might be tied to this new arrival, the symptom picture looks familiar, but the science behind the variant tells a more complicated story.
Where BA.3.2 Came From and How It Got Here
The earliest documented sample of BA.3.2 dates to November 22, 2024, according to the WHO variant tracking. The strain was first identified in South Africa and spent roughly a year circulating internationally before gaining a foothold in the United States. The CDC has been monitoring BA.3.2 through its multimodal genomic surveillance system, tracking the variant’s emergence and spread both domestically and worldwide from November 2024 through February 2026, as detailed in a surveillance report.
The WHO conducted an initial risk evaluation for BA.3.2 on December 5, 2025, and its Technical Advisory Group on COVID-19 Vaccine Composition listed the variant among “potentially emerging” strains for which neutralization data were requested ahead of vaccine composition decisions. That request signals that scientists recognized early on that BA.3.2 might be different enough from prior strains to affect vaccine performance and wanted laboratory evidence in hand before recommending any changes.
What Makes the ‘Cicada’ Variant Genetically Distinct
BA.3.2 is not just another incremental mutation. Peer-reviewed research published in the journal Virus Evolution characterized the variant’s phylogenetic origin and laboratory properties, identifying an 871 base-pair deletion affecting the ORF7 and ORF8 regions of the virus. These regions play roles in how the virus interacts with the host immune system, and large deletions in this area can alter how effectively antibodies from prior infection or vaccination neutralize the virus.
The same study examined BA.3.2’s neutralization escape patterns using live virus and plasma samples, comparing the variant against LP.8.1 and JN.1-related lineages. The findings help explain why BA.3.2 has been able to gain ground so quickly: it is genetically distinct enough from the variants that have dominated U.S. transmission in recent years that many Americans may have limited immune recognition of it. As one infectious disease physician noted in an analysis for The Conversation, BA.3.2 is “almost a complete stranger” to immune systems shaped by earlier Omicron waves.
That unfamiliarity does not automatically mean more severe disease, but it can translate into more infections, including in people who were recently sick with COVID-19 or received updated vaccines. Laboratory work is ongoing to determine how much protection current vaccine formulations and prior infections provide against BA.3.2.
Symptoms to Watch For Right Now
No BA.3.2-specific symptom profile has been confirmed by health authorities. That gap in the data is important to interpret correctly: it does not mean the variant causes identical illness to earlier strains, only that researchers have not yet published evidence of clearly different patterns. For now, the CDC maintains a standard symptom list that applies across variants, and the agency emphasizes that this list may evolve as more evidence accumulates.
The symptoms to monitor include:
- Fever or chills
- Cough
- Shortness of breath or difficulty breathing
- Fatigue
- Muscle or body aches
- New loss of taste or smell
- Sore throat
- Congestion or runny nose
- Nausea, vomiting, or diarrhea
Because BA.3.2’s large ORF7/ORF8 deletion could theoretically alter how the immune system responds to infection, symptom patterns may shift as more clinical data accumulate. For example, shifts in immune response might influence how quickly symptoms begin or how long they last, even if the types of symptoms remain similar. Anyone experiencing these signs should treat them as potentially COVID-related, especially given how quickly the “Cicada” variant is spreading in the U.S..
People who prefer to read health information in Spanish can find a parallel overview of COVID-19 síntomas from the CDC, which highlights the same core warning signs and advises seeking urgent care for trouble breathing, chest pain, confusion, or bluish lips or face.
Testing, Treatment, and When to Seek Care
Because BA.3.2 is a form of SARS-CoV-2, existing rapid antigen tests and PCR tests are still used to diagnose infection. Genomic sequencing is needed to distinguish BA.3.2 from other variants, so most people will only see “COVID-19 positive” on their test result, not a specific lineage name. Public health laboratories and some large health systems send samples for sequencing to track which variants are driving local surges.
Treatments also remain the same. Antiviral medications such as nirmatrelvir-ritonavir (Paxlovid) and other authorized therapies are still recommended for people at higher risk of severe disease, including older adults and those with underlying health conditions. Decisions about treatment are based on risk factors and timing of symptom onset, not on whether the infection is caused by BA.3.2 or another lineage.
People should seek urgent or emergency care if they develop warning signs such as difficulty breathing, persistent chest pain or pressure, new confusion, inability to stay awake, or bluish lips or face. These danger signs warrant immediate evaluation regardless of the suspected variant.
What to Do If You Get Sick
The CDC’s updated respiratory virus guidance, which applies to COVID-19, influenza, and RSV alike, offers a straightforward protocol. People who are sick should stay home and can return to normal activities once symptoms have been improving for at least 24 hours and any fever has been gone for 24 hours without the use of fever-reducing medicine. That dual threshold (both symptom improvement and fever resolution) is the key benchmark.
This unified guidance replaced earlier, more complex isolation timelines and applies regardless of which variant is causing the illness. For BA.3.2 specifically, no separate isolation protocol has been issued. The practical takeaway: the same stay-home rules apply, but people should remain alert to the possibility that a spring or summer illness that feels like a “regular cold” could in fact be COVID-19 driven by the Cicada variant.
During the stay-home period, people are advised to rest, stay hydrated, and avoid close contact with others, especially those at higher risk for severe disease. When they do resume normal activities, additional precautions such as masking in crowded indoor spaces and improving ventilation for several more days can further reduce the chance of passing the virus to others.
How Vaccines and Prior Immunity May Hold Up
Scientists are still working to understand how well existing vaccines protect against BA.3.2. The WHO’s request for neutralization data on emerging variants, including BA.3.2, underscores the need for laboratory studies that compare antibody responses across lineages. These experiments typically measure how well blood samples from vaccinated or previously infected people can block the new variant in cell culture.
Early laboratory findings suggest that BA.3.2 can partially evade antibodies generated by prior Omicron infections and updated vaccines, but cellular immune responses (which help prevent severe disease) are expected to remain more durable. That means breakthrough infections are possible, yet vaccines are still likely to reduce the risk of hospitalization and death.
Public health agencies continue to recommend staying up to date with COVID-19 vaccinations, especially for older adults, people with chronic medical conditions, pregnant individuals, and those with weakened immune systems. As more data on BA.3.2 become available, advisory groups will use that evidence to decide whether future vaccine updates are needed.
Staying Informed as the Cicada Variant Spreads
For now, experts emphasize that the tools developed over the past four years, testing, ventilation, masking in high-risk settings, antiviral treatment, and vaccination, still work against BA.3.2. What changes with a variant like Cicada is not the basic playbook but the urgency of using those tools consistently when cases rise.
Local health departments and national agencies are expected to update their guidance as new evidence emerges about BA.3.2’s transmissibility, severity, and vaccine performance. People who want to track developments can follow official updates from the CDC and WHO, along with in-depth explainers from science communicators and physicians who translate emerging research into practical advice.
In the meantime, paying attention to familiar symptoms, testing promptly, staying home when sick, and keeping vaccinations current remain the most reliable ways to navigate this latest chapter of the pandemic, even as the virus continues to evolve.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
